Tesamorelin 6mg + Ipamorelin 2mg Review

This review examines the combination vial containing Tesamorelin (6 mg) and Ipamorelin (2 mg), two mechanistically distinct growth-hormone secretagogues that are frequently co-investigated in pre-clinical and translational research settings. The review covers the chemistry and origin of each peptide, their individual and synergistic mechanisms at the pituitary and hypothalamic level, the published human and animal study landscape, pharmacokinetic profiles, purity verification, and how this vial stacks up against related research compounds available in the same catalog category.

Both peptides act on the somatotropic axis but through distinct receptor populations, which is precisely why researchers pair them. Tesamorelin acts through the growth-hormone-releasing hormone (GHRH) receptor, recapitulating endogenous pulsatile GH release physiology. Ipamorelin acts through the ghrelin receptor (GHS-R1a) with high selectivity and minimal off-target effects on cortisol and prolactin, unlike earlier generation secretagogues. Together, they represent a dual-pathway stimulation paradigm that a growing body of preclinical literature supports as producing supra-additive GH pulse amplitudes.

The vial reviewed here is supplied by Apollo Peptide Sciences. Before reading further, confirm that your institution holds the appropriate research licenses and biosafety documentation for peptide hormone research. For guidance on reconstitution technique, see our peptide reconstitution guide.

Editor's Verdict

The Tesamorelin 6 mg + Ipamorelin 2 mg combination vial represents one of the most mechanistically coherent pairings in the current research-peptide catalog. Tesamorelin brings a well-characterized clinical track record, being the only GHRH analogue with FDA approval (as Egrifta, for HIV-associated lipodystrophy), which means its pharmacology is documented in large, controlled human trials rather than relying solely on animal data. ^[1] Ipamorelin contributes high GHS-R1a selectivity, a pharmacokinetic profile compatible with pulsatile dosing paradigms, and a favorable side-effect architecture that avoids the cortisol and aldosterone elevation seen with GHRP-2 and GHRP-6. ^[2]

From a research-design standpoint, this combination is attractive precisely because each peptide has an independent, well-characterized receptor mechanism. Investigators can therefore attribute observed downstream effects to either the GHRH-R or GHS-R1a pathway, or to their synergistic interaction, with a reasonable degree of mechanistic confidence. The ratio of 3:1 (tesamorelin:ipamorelin by mass) in this vial is broadly consistent with the proportions used in combination-secretagogue pilot studies, though researchers should note that literature-reported animal-equivalent doses vary considerably across species and experimental endpoints.

The price point of $60.00 for a combination vial is competitive within the vendor landscape. A comparable combined mass from separate vials would typically cost $80-100 across most catalog suppliers, so there is a modest efficiency argument for combination packaging when both agents are planned for the same experimental protocol. See the full product page for current availability.

Specifications

What It Is: Chemistry, Origin, and Sequence Detail

Tesamorelin: A Stabilized GHRH Analogue

Tesamorelin is a synthetic analogue of endogenous human growth-hormone-releasing hormone (hGHRH), the 44-amino-acid hypothalamic neuropeptide that drives pulsatile GH secretion from anterior pituitary somatotrophs. Endogenous GHRH is rapidly degraded by dipeptidyl peptidase IV (DPP-IV) at the Ala2 position, yielding a circulating half-life of only 2-7 minutes. ^[3] Tesamorelin addresses this limitation through a single structural modification: the addition of a trans-3-hexenoic acid moiety covalently attached to the N-terminus of the full-length GHRH(1-44)-amide sequence. This modification confers DPP-IV resistance while preserving full receptor-binding affinity and intrinsic activity at the GHRH receptor.

The full sequence of tesamorelin retains all 44 amino acids of native GHRH(1-44), including the critical pharmacophore region spanning residues 1-29 that is responsible for receptor activation. The C-terminal amidation (replacing the free carboxylate of the 44th amino acid, methionine) is a feature shared with native GHRH and is retained in tesamorelin. The N-terminal hexenoyl group does not participate in receptor contacts but serves a purely protective pharmacokinetic function by sterically occluding the DPP-IV cleavage site. ^[3]

Tesamorelin was developed by Theratechnologies (Montreal, Canada) and received FDA approval in November 2010 under the brand name Egrifta for the specific indication of reducing excess abdominal fat in adults with HIV-associated lipodystrophy. ^[1] This clinical history is significant in a research context because it means that large Phase III randomized controlled trials were conducted in humans, generating pharmacokinetic, pharmacodynamic, and safety data that are not available for most research peptides. The existence of an approved pharmaceutical-grade reference standard also facilitates analytical validation of research-grade material.

Ipamorelin: A Selective Pentapeptide GHS-R1a Agonist

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib denotes alpha-aminoisobutyric acid and D-2-Nal denotes the D-enantiomer of beta-(2-naphthyl)alanine. It was discovered and characterized by Novo Nordisk researchers Raun et al. in the late 1990s, with the seminal description published in 1998. ^[2] The compound emerged from a medicinal-chemistry program aimed at identifying ghrelin receptor agonists with improved selectivity over earlier growth-hormone-releasing peptides (GHRPs).

The structural features that define ipamorelin's pharmacology are instructive. The Aib residue at position 1 introduces conformational rigidity and protease resistance. The D-amino acid residues at positions 3 (D-2-Nal) and 4 (D-Phe) are critical for GHS-R1a binding affinity and confer resistance to peptidase degradation by preventing recognition by endo- and exopeptidases that preferentially cleave L-configured substrates. The C-terminal amide stabilizes the compound against carboxypeptidase cleavage. Together, these modifications yield a metabolic stability profile markedly superior to the linear natural sequence. ^[2]

Relative to GHRP-2 and GHRP-6, the two earlier-generation GHS-R1a agonists most frequently encountered in research catalogs, ipamorelin demonstrates substantially reduced efficacy at corticotroph GHS-R subtypes and mineralocorticoid pathways. Raun et al. showed in the original characterization study that ipamorelin's plasma cortisol response was minimal compared to GHRP-6 at equimolar doses in rats. ^[2] This selectivity is not merely an academic distinction; for research designs investigating GH-dependent anabolic or metabolic endpoints, confounding glucocorticoid elevation is a significant source of experimental noise, and ipamorelin's clean profile helps control for this.

The molecular weight of ipamorelin (approximately 711.9 Da) is substantially smaller than tesamorelin (approximately 5135.9 Da), and this difference is reflected in their distinct pharmacokinetic behaviors, particularly in terms of renal clearance kinetics and volume of distribution.

Mechanism of Action

GHRH Receptor Activation by Tesamorelin

The GHRH receptor (GHRH-R) is a class B G-protein-coupled receptor (GPCR) expressed predominantly on anterior pituitary somatotrophs and, at lower levels, in peripheral tissues including the heart, lung, kidney, and immune cells. ^[4] Upon tesamorelin binding, the receptor undergoes a conformational change that couples to Gs-alpha subunits, activating adenylyl cyclase. The resulting increase in intracellular cyclic AMP (cAMP) activates protein kinase A (PKA), which phosphorylates the transcription factor CREB (cAMP-response element binding protein) at Ser133. Phospho-CREB drives transcription of the GH gene and upregulates somatotroph responsiveness to subsequent GHRH pulses. ^[4]

PKA activation also opens voltage-gated calcium channels, raising intracellular calcium concentrations and triggering exocytosis of GH-containing secretory vesicles. This dual mechanism (transcriptional upregulation and rapid vesicular release) accounts for the physiologically appropriate, pulse-like GH secretion that GHRH analogues produce, in contrast to the more pharmacologically forced release seen with some non-physiological secretagogues. The pulse amplitude produced by tesamorelin is dose-dependent within the concentration range studied in clinical trials (1-2 mg subcutaneous in humans). ^[5]

An important downstream consequence of cAMP/PKA signaling in somatotrophs is the upregulation of GH receptor synthesis in peripheral tissues, particularly in the liver where IGF-1 is produced in response to GH. Tesamorelin administration in clinical studies consistently elevates plasma IGF-1 levels, confirming activation of the full GH-IGF-1 axis. ^[1] In HIV-lipodystrophy trials, this IGF-1 elevation was associated with measurable reductions in visceral adipose tissue, mediated in part through GH-stimulated lipolysis in visceral fat depots. ^[6]

GHS-R1a Activation by Ipamorelin

The ghrelin receptor (GHS-R1a) is a class A GPCR that, like GHRH-R, is expressed on pituitary somatotrophs but also on hypothalamic neurons, vagal afferents, pancreatic cells, and in the gastrointestinal tract. ^[7] The GHS-R1a signal transduction cascade differs fundamentally from GHRH-R: agonist binding couples the receptor to Gq/11 proteins, activating phospholipase C-beta (PLC-beta). PLC-beta hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The combined calcium surge and PKC activation trigger GH vesicle exocytosis through mechanisms partially distinct from those activated by the GHRH-R/cAMP pathway. ^[7]

GHS-R1a also signals through arrestin-dependent pathways upon ligand binding, leading to receptor internalization and contributing to desensitization kinetics that are relevant for intermittent-dosing research paradigms. The receptor constitutive activity (GHS-R1a exhibits about 50% of maximum signaling in the absence of agonist) has been documented and is relevant to experimental design when using inverse agonists as controls. ^[8]

Ipamorelin's selectivity for GHS-R1a over related receptors including the GHS-R1b splice variant, the motilin receptor, and the CD36 scavenger receptor is a key pharmacological advantage for mechanistic research. When investigators need to confirm that observed GH responses are GHS-R1a-mediated, ipamorelin's narrow receptor footprint simplifies interpretation compared with GHRP-6, which has multiple receptor interactions. ^[2]

Synergistic Interactions at the Somatotroph Level

The mechanistic rationale for combining GHRH analogues with GHS-R1a agonists rests on the convergence of their respective intracellular signaling cascades at the level of GH secretory vesicle exocytosis. The cAMP/PKA pathway activated by tesamorelin and the IP3/DAG/calcium pathway activated by ipamorelin both promote exocytosis, but through different molecular effectors. Pre-loading somatotrophs with elevated cAMP (via GHRH-R activation) substantially sensitizes the calcium-dependent exocytotic machinery to subsequent IP3-mediated calcium mobilization. The result is a GH pulse amplitude that exceeds what either compound produces individually. ^[9]

Hartman et al. demonstrated in human subjects that the combination of GHRH with a GHS-R1a agonist produced GH pulses of greater amplitude than either agent alone, with the combination yielding a supra-additive (synergistic rather than merely additive) GH response. ^[9] The synergy is particularly pronounced at low doses of each compound, which is relevant for research protocols aiming to study near-physiological GH axis activation.

Peripheral Tissue Distribution and Secondary Effectors

Beyond the pituitary, both receptors are expressed in peripheral tissues that are themselves relevant research targets. GHRH-R expression in cardiac myocytes has been documented, and direct cardioprotective effects of GHRH analogues independent of pituitary GH release have been investigated in animal models. ^[10] GHS-R1a expression in the arcuate nucleus of the hypothalamus means ipamorelin also activates hypothalamic circuits governing appetite, sleep-wake transitions, and growth-axis feedback. The sleep-promoting effects attributed to GHS-R1a agonists appear to be mediated at least in part through these hypothalamic GHS-R1a populations, distinct from the pituitary somatotroph pathway. ^[11]

The IGF-1 produced downstream of GH signaling in hepatocytes acts as a classical endocrine mediator at muscle, bone, adipose tissue, and brain. In muscle, IGF-1 activates the IGF-1 receptor/PI3K/Akt/mTORC1 cascade to promote protein synthesis and inhibit protein degradation. In bone, IGF-1 promotes osteoblast proliferation and collagen synthesis. These downstream effects are why GH secretagogue research intersects with muscle-growth, longevity, and bone-density research programs. ^[12]

What the Research Says

Tesamorelin in HIV-Associated Lipodystrophy: The Phase III Clinical Trials

The most extensive human clinical data for any GHRH analogue comes from the two pivotal Phase III randomized controlled trials of tesamorelin in HIV-infected adults with excess visceral adipose tissue (VAT), published by Falutz et al. in 2007 and 2010. ^[6] The 2007 study enrolled 412 patients and randomized them 2:1 to tesamorelin 2 mg subcutaneously daily versus placebo for 26 weeks. The primary endpoint was the change in VAT measured by CT scan. Tesamorelin-treated subjects showed a mean VAT reduction of 15.2% from baseline, compared with a 5.0% increase in the placebo group (treatment difference approximately 20%, p less than 0.0001). Secondary endpoints including trunk-to-limb fat ratio and patient-reported body image scores also favored tesamorelin. ^[6]

The mechanism underlying visceral fat reduction involves GH-stimulated lipolysis in visceral adipocytes, which express GH receptors at higher density than subcutaneous adipocytes, making them preferentially responsive to GH-axis activation. Hepatic lipase activity, fatty acid oxidation, and triglyceride clearance are all enhanced by GH elevation, contributing to the reduction in VAT. Plasma IGF-1 in the tesamorelin arm rose from baseline by approximately 131 mcg/L, confirming functional GH-axis activation. ^[6]

From a research-translation perspective, these trials are important for several reasons. First, they confirm that a GHRH analogue can produce clinically meaningful metabolic remodeling through a purely physiological mechanism (enhanced pulsatile GH secretion) without the adverse consequences seen with exogenous GH administration at supraphysiological doses. Second, the safety data from over 800 patient-years of exposure provide a detailed adverse-event profile that informs preclinical research risk assessment. Third, the dose used (2 mg daily) establishes a benchmark against which in-vivo research doses in animal models can be scaled using established body-surface-area conversion factors.

Ipamorelin in Rat Growth and GH Pulse Studies: Raun et al. 1998

The foundational characterization study of ipamorelin by Raun et al. (1998) remains the most-cited preclinical reference for this compound. ^[2] The study used male Sprague-Dawley rats across several experimental arms. In the primary pharmacology arm, rats received a single intravenous bolus of ipamorelin (0.1, 0.3, 1.0, or 3.0 nmol/kg), GHRP-6 (1.0 nmol/kg), or vehicle, and plasma GH was measured at 5, 15, 30, 45, and 60 minutes post-dose. Ipamorelin produced dose-dependent GH pulses with peak values at 5-15 minutes, with the 1.0 nmol/kg dose producing a GH peak comparable to that of GHRP-6 1.0 nmol/kg.

The critical selectivity data came from the cortisol, ACTH, and aldosterone measurements at equivalent GH-stimulating doses. GHRP-6 at 1.0 nmol/kg produced significant elevation of plasma ACTH (approximately 4.5-fold increase over baseline), while ipamorelin at the same dose produced no statistically significant ACTH change. Cortisol responses followed a similar pattern. This result directly demonstrated ipamorelin's pharmacological selectivity for somatotroph GHS-R1a over the corticotroph pathways activated by GHRP-6. ^[2]

A second arm of the Raun study examined chronic daily ipamorelin administration (subcutaneous, 125 mcg/kg twice daily) for 15 days and measured tibial width as a surrogate for skeletal growth stimulation. Ipamorelin-treated rats showed significantly greater tibial width increase compared to vehicle controls, consistent with GH/IGF-1-dependent linear bone growth. This finding established the translational relevance of ipamorelin for muscle-growth and bone-metabolism research programs. ^[2]

The study's main limitation is its exclusive reliance on male rats, a species and sex whose GH secretion pattern (continuous rather than pulsatile in female rats) may not translate directly to human GH physiology. Dose extrapolation from rats to larger mammals requires careful body-surface-area correction, and researchers should consult dosing-conversion literature rather than applying rat doses directly to other species.

Ipamorelin and Sleep Architecture: Deep Slow-Wave Sleep Studies

GHS-R1a agonists as a class have been observed to promote slow-wave sleep (SWS) and increase nocturnal GH secretion in a pattern consistent with the normal sleep-GH relationship. Frieboes et al. (1995) characterized the sleep-promoting effects of GHRP-6 in humans, providing a mechanistic framework for understanding ipamorelin's sleep-relevant pharmacology. ^[11] Healthy male volunteers received GHRP-6 or placebo IV at sleep onset, and polysomnography showed that GHRP-6 increased SWS (specifically Stage 3 and 4 NREM sleep) during the first sleep cycle, concurrent with an elevated nocturnal GH pulse. ^[11]

Although this study used GHRP-6 rather than ipamorelin, the mechanism is GHS-R1a-mediated, making the findings pharmacologically relevant to ipamorelin research. GHS-R1a agonism in the hypothalamic ventromedial nucleus and arcuate nucleus promotes the neuronal firing patterns associated with SWS generation. The GH pulse that follows SWS onset may itself feedback on sleep consolidation through GH-receptor signaling in sleep regulatory circuits. For longevity research, the SWS-promoting property of GHS-R1a agonists is especially interesting because SWS declines progressively with age and is associated with impaired anabolic hormone secretion, reduced synaptic consolidation, and increased cardiovascular risk. ^[11]

Researchers designing sleep-relevant ipamorelin studies should note that the optimal timing of secretagogue administration in nocturnal protocols appears to be at or shortly after sleep onset rather than during the daytime, based on the interaction between endogenous GHRH pulsatility and the circadian GH axis. The combination of tesamorelin (GHRH-R) and ipamorelin (GHS-R1a) in sleep-architecture protocols would allow simultaneous investigation of both hypothalamic input pathways to the somatotroph, a design that has been proposed but not yet fully executed in large controlled human studies, representing an open research opportunity.

Tesamorelin and Cognitive Function: Cognitive Outcomes in Older Adults

Friedman et al. (2013) conducted a randomized, double-blind, placebo-controlled trial of tesamorelin in 152 older adults (mean age 68 years, GH-deficient by IGF-1 criteria) examining cognitive outcomes over 20 weeks. ^[13] Participants received tesamorelin 1 mg subcutaneously daily or placebo. The primary cognitive endpoint was performance on a standardized battery measuring executive function and verbal memory. Tesamorelin-treated subjects showed statistically significant improvements in executive function composite scores compared to placebo (p = 0.02), with a treatment effect size of 0.32 standard deviations. Verbal memory also improved, though not significantly after multiple-comparisons correction.

These findings are relevant to longevity-focused GH-secretagogue research because age-related GH/IGF-1 axis decline has been implicated in the cognitive decline phenotype of normal aging. The study used a GHRH analogue rather than exogenous GH specifically to avoid the supraphysiological IGF-1 elevations associated with exogenous GH, which carry their own risk profile. Tesamorelin produced a mean IGF-1 increase of approximately 67 mcg/L, remaining within the normal adult reference range, which may explain the favorable cognitive safety profile observed. ^[13]

The study's limitations include its relatively short duration (20 weeks), single GHRH analogue tested, and the absence of neuroimaging data to identify the neural substrates of cognitive improvement. Whether the cognitive benefits observed would be enhanced by co-administration of a GHS-R1a agonist (thereby also mobilizing hypothalamic sleep/memory circuits) remains an open research question with direct relevance to this combination vial's intended research applications.

Additional Preclinical Studies: Body Composition and Muscle Anabolism

Nass et al. (2008) conducted a six-month pilot study of GHRH(1-29)-NH2 (sermorelin) in healthy older adults, providing a comparison point for GHRH analogue effects on body composition in the aging population. ^[14] While tesamorelin was not the specific compound tested, the study's body-composition endpoints (dual-energy X-ray absorptiometry for lean mass and fat mass) and the GHRH-receptor pharmacology are directly translatable. Subjects receiving active GHRH analogue showed significant increases in lean body mass (mean +2.5 kg) and decreases in fat mass (mean -1.8 kg) versus placebo over six months, consistent with GH/IGF-1-mediated protein anabolic and lipolytic effects. ^[14]

For muscle-growth research applications, the IGF-1 axis activation downstream of GH secretagogue administration is the proximate anabolic driver. Research by Philippou et al. has characterized the multiple IGF-1 isoforms (systemic endocrine IGF-1, liver-derived; and mechano-growth factor, locally produced in contracting muscle) that contribute to muscle hypertrophy, providing a molecular framework for interpreting secretagogue-driven anabolic responses. ^[12] Investigators combining secretagogue treatment with mechanical loading models should measure both circulating IGF-1 and local muscle IGF-1 splice variants to capture the full picture.

Pharmacokinetics

The pharmacokinetic profile of tesamorelin is well characterized from its clinical development program. Following subcutaneous administration in humans, tesamorelin reaches maximum plasma concentration (Cmax) in approximately 15-30 minutes, with a terminal half-life of approximately 38 minutes. ^[5] The absolute subcutaneous bioavailability is approximately 4-5%, which is low but consistent with other peptide drugs of this molecular weight class administered subcutaneously. The low bioavailability reflects both limited lymphatic absorption and rapid peptidase degradation in the subcutaneous space and during first-pass clearance. Despite low bioavailability by mass, the pharmacodynamic response (GH pulse) is robust because the pituitary is highly sensitive to even brief, transient GHRH-R stimulation. ^[5]

Ipamorelin's pharmacokinetics are less completely characterized in the published literature, primarily because the compound did not progress through clinical development to the same extent as tesamorelin. The available preclinical data from rat studies indicate a half-life of approximately 2 hours following subcutaneous administration, substantially longer than tesamorelin. ^[2] The longer half-life of ipamorelin likely reflects its smaller molecular size (lower renal clearance threshold overlap), D-amino acid stabilization, and relatively slower peptidase degradation kinetics in plasma. For research dosing frequency, this kinetic asymmetry between the two compounds is practically relevant: tesamorelin's shorter half-life means that once-daily dosing produces a single GH pulse, while ipamorelin's longer duration of action may produce a more sustained receptor activation window.

For researchers designing in-vivo protocols using this combination, the differential pharmacokinetics suggest that simultaneous administration may not optimally synchronize receptor-activation events. Some research groups administer the GHRH analogue slightly before the GHS-R1a agonist to take advantage of cAMP pre-sensitization of somatotrophs, as discussed in the mechanism section. The optimal timing interval between agents has not been systematically characterized in the combination context; this remains an open experimental design question. For reconstitution and dosage calculation guidance specific to this vial, see our reconstitution guide and dosage calculation guide.

Purity and Verification

What to Expect on a Certificate of Analysis

A certificate of analysis (CoA) from a reputable research peptide supplier should include, at minimum, the following analytical data for each peptide in a combination vial: peptide identity confirmed by mass spectrometry (MS), purity by high-performance liquid chromatography (HPLC), and total peptide content by amino acid analysis or UV absorbance at 280 nm. ^[15]

For tesamorelin, the expected HPLC purity specification for research-grade material is greater than or equal to 98%, verified by reversed-phase HPLC with UV detection at 214 nm (peptide bond absorbance). The mass spectrometry result should confirm a [M+H]+ ion or multiply charged ions consistent with the calculated molecular weight of 5135.9 Da within a tolerance of plus or minus 0.01% (approximately plus or minus 0.5 Da). The HPLC chromatogram should show a single dominant peak with no shoulders or satellite peaks that would indicate truncated sequences, oxidized methionine variants, or diastereomeric impurities.

For ipamorelin, purity expectations are similar (greater than or equal to 98% HPLC), and mass spectrometry confirmation is straightforward given the low molecular weight (711.9 Da), which is easily resolved by electrospray ionization mass spectrometry (ESI-MS) with high mass accuracy. Researchers should confirm that the D-amino acid configuration is specified in the CoA or the accompanying analytical report; many suppliers confirm this by chiral HPLC or by circular dichroism, though these are not universal.

Independent Third-Party Verification

For high-stakes research applications, independent verification of peptide identity and purity is strongly recommended and is standard practice in many academic research settings. The most practical approach is to submit a small aliquot (typically 0.5-1.0 mg) from the research vial to an independent analytical laboratory for HPLC and MS analysis before use in experiments. Several contract analytical chemistry services routinely perform peptide identity confirmation by ESI-MS and purity quantification by RP-HPLC for fees that are modest relative to the cost of failed experiments.

When comparing the independent analytical result to the supplier-provided CoA, researchers should look for concordance within the analytical uncertainty of both methods (typically plus or minus 1% for HPLC purity, plus or minus 0.05% for MS molecular weight). Significant discrepancies in purity (greater than 3% deviation) or unexpected secondary peaks in the HPLC trace warrant contacting the supplier for explanation or requesting a replacement vial from a different lot.

For guidance on reading CoA documents and selecting suppliers with robust quality-assurance programs, see our supplier evaluation guide. Apollo Peptide Sciences provides lot-specific CoA documentation, accessible by QR code on each vial label, which is consistent with current industry best-practice for research-grade peptide distribution.

Dosage and Reconstitution

Reconstitution Procedure

Lyophilized peptide powders require reconstitution in an aqueous solvent before use in in-vivo or in-vitro research applications. For this combination vial, bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) is the standard reconstitution vehicle. Bacteriostatic water extends post-reconstitution stability to approximately 14-28 days at 2-8°C compared with 3-5 days for reconstitution with sterile water alone, due to benzyl alcohol's antimicrobial properties. ^[16]

The reconstitution procedure for peptide research applications is detailed in our peptide reconstitution guide. In brief, the reconstitution volume selected determines the resulting concentration. For this 8 mg total peptide mass vial (6 mg tesamorelin + 2 mg ipamorelin), common laboratory reconstitution volumes and resulting concentrations are as follows:

Worked Example 1 - Standard Research Concentration: Add 2 mL of bacteriostatic water to the vial. Final concentration: Tesamorelin 3 mg/mL (3000 mcg/mL) + Ipamorelin 1 mg/mL (1000 mcg/mL). This concentration is suitable for rodent in-vivo studies using sub-milliliter injection volumes.

Worked Example 2 - Dilute Concentration for Low-Dose Protocols: Add 4 mL of bacteriostatic water to the vial. Final concentration: Tesamorelin 1.5 mg/mL (1500 mcg/mL) + Ipamorelin 0.5 mg/mL (500 mcg/mL). This dilution reduces volume-per-dose error when precise small doses are required.

Worked Example 3 - In-Vitro Cell Study Concentration: For cell-based assays, reconstitute in sterile phosphate-buffered saline (PBS) at 10 mL total volume to yield 0.6 mg/mL tesamorelin + 0.2 mg/mL ipamorelin as a stock solution, then serial-dilute to working concentrations (typically 1 nM - 1 microM range for receptor binding and signaling assays).

Literature-Reported Research Doses

In the clinical literature, tesamorelin was administered at 2 mg subcutaneously once daily in the HIV-lipodystrophy Phase III trials. ^[6] In the Friedman cognitive outcomes trial, 1 mg subcutaneously once daily was the research dose studied. ^[13] In-vivo rat studies of tesamorelin have used doses scaled proportionally to the clinical dose using the FDA body-surface-area conversion factor (human-to-rat conversion factor of approximately 6.2x based on body surface area per unit body weight). A 2 mg/day human dose converts to an animal-equivalent rat dose of approximately 0.3 mg/kg/day using this scaling method.

For ipamorelin, the Raun et al. rat study used intravenous doses of 0.1-3.0 nmol/kg and subcutaneous doses of approximately 125-500 mcg/kg. ^[2] For in-vitro receptor binding assays, EC50 values for GHS-R1a activation by ipamorelin have been reported in the 1-10 nM range across multiple assay formats. ^[2]

For detailed guidance on dose calculation methodology, including body-surface-area scaling between species, unit conversions, and dilution series planning, see our dosage calculation guide.

Storage After Reconstitution

Reconstituted tesamorelin and ipamorelin should be stored at 2-8°C (standard laboratory refrigerator), protected from light. Repeated freeze-thaw cycles of reconstituted peptide solutions are associated with aggregation, degradation, and loss of biological activity, and should be avoided. If storage beyond 14 days is required, the unconstituted lyophilized powder can be re-stored at -20°C for extended periods (typically 24 months from manufacture date when properly desiccated). Reconstituted aliquots should not be refrozen after use.

Side Effects and Safety

Safety Data from Tesamorelin Clinical Trials

The tesamorelin clinical safety database, derived from the two Phase III trials and long-term extension studies, provides the most rigorous safety characterization available for any compound in this vial. ^[6] The most common adverse events in tesamorelin-treated subjects (greater than 5% incidence) were injection-site reactions (including pain, erythema, and induration), arthralgia, peripheral edema, and myalgia. These events are consistent with the known pharmacology of GH axis activation, since GH promotes sodium and water retention and has musculoskeletal effects at elevated circulating levels.

Glucose metabolism effects were monitored closely in the clinical trials given the known diabetogenic potential of chronic GH elevation. Tesamorelin treatment was associated with small but statistically significant increases in fasting glucose (mean increase approximately 2 mg/dL) and HbA1c in some subgroups. In HIV-infected subjects with pre-existing metabolic syndrome risk factors, glucose monitoring was recommended throughout the treatment period. The magnitude of glucose effect was substantially smaller than that reported with exogenous GH administration at similar GH-equivalent doses, consistent with the physiological pulsatile GH release pattern produced by GHRH analogues versus the sustained supraphysiological GH exposure from exogenous GH injection. ^[5]

Antibody formation against tesamorelin was detected in a subset of clinical trial participants (approximately 49% developed IgG antibodies by 26 weeks). Importantly, the presence of anti-tesamorelin antibodies was not associated with reduced efficacy or increased adverse events in most subjects, suggesting limited clinical significance. Cross-reactivity with endogenous GHRH was tested and found to be low, allaying concerns about long-term perturbation of endogenous GHRH function. ^[6]

Safety Considerations for Ipamorelin

Ipamorelin's safety profile in preclinical studies is characterized primarily by its selectivity data. As described in the mechanism section, ipamorelin does not produce significant cortisol, ACTH, or aldosterone elevation at GH-stimulating doses, which distinguishes it from GHRP-2 and GHRP-6 in this regard. ^[2] In longer-term rat studies, daily ipamorelin administration for 15 days did not produce organ toxicity on histopathological examination of liver, kidney, and pituitary. ^[2]

The potential for GHS-R1a agonists to stimulate appetite (ghrelin itself is orogenic through hypothalamic circuits) is a known class effect. In animal studies, ipamorelin has shown less appetite stimulation than ghrelin or GHRP-6, consistent with its more restricted receptor activity profile, but appetite effects should be monitored in in-vivo research protocols. ^[7]

Fluid retention and potential for pituitary axis feedback perturbation with chronic administration are theoretical concerns extrapolated from GHRH/GHS class pharmacology. No long-term human safety data exists for ipamorelin, and researchers should design appropriate washout periods into chronic-administration study protocols.

How It Compares

Tesamorelin vs. Sermorelin

Sermorelin is GHRH(1-29)-NH2, the minimally active fragment of the GHRH sequence, and was historically the most studied GHRH analogue before tesamorelin's clinical development. The primary pharmacological difference between sermorelin and tesamorelin is the latter's retention of the full 44-amino-acid sequence and the addition of the N-terminal hexenoyl modification. In receptor-binding studies, tesamorelin and the full-length GHRH(1-44) peptide show higher receptor affinity and longer-duration signaling than sermorelin, which reflects contributions from C-terminal residues of GHRH to receptor contact and stabilization. ^[17] For researchers specifically studying the GHRH-GHRH-R interaction, tesamorelin is the preferred tool when the goal is to produce maximal, physiologically representative pituitary stimulation.

Tesamorelin vs. CJC-1295 with DAC

CJC-1295 with drug-affinity complex (DAC) is a GHRH analogue modified with a lysine-reactive maleimido group that covalently binds to serum albumin, dramatically extending its half-life to approximately 6-8 days. ^[18] This extended half-life is an advantage for some research designs (less frequent dosing, sustained GH axis activation) but may actually be a disadvantage for research aiming to study pulsatile GH secretion physiology, because chronic GHRH-R stimulation desensitizes somatotrophs and blunts pulse amplitude over time. Tesamorelin's shorter half-life preserves pulsatile dynamics more faithfully. Researchers who need sustained GHRH-R occupation should consider CJC-1295 with DAC; those who need physiologically pulsatile GH stimulation should prefer tesamorelin.

Ipamorelin vs. GHRP-2 and GHRP-6

Both GHRP-2 and GHRP-6 are hexapeptide GHS-R1a agonists with well-established activity profiles but inferior selectivity versus ipamorelin. GHRP-6's significant stimulation of appetite via the ghrelin pathway and its ACTH/cortisol elevation make it less suitable for clean GH-axis research. GHRP-2 has a somewhat cleaner profile than GHRP-6 but still produces detectable cortisol elevation at effective GH-stimulating doses. For research designs where isolated GH-axis stimulation without glucocorticoid confounding is the goal, ipamorelin is pharmacologically superior. The selectivity advantage of ipamorelin is especially important in longer-duration in-vivo studies where cumulative cortisol exposure would be expected to exert catabolic effects opposing the anabolic GH/IGF-1 axis.

The Combination Advantage Over Single Agents

The core research argument for using this combination vial over either compound alone is the synergistic GH pulse amplitude documented when GHRH-R and GHS-R1a pathways are co-activated. ^[9] For research applications where maximizing GH pulse amplitude within a physiological range is the goal (such as studying GH-dependent metabolic remodeling or muscle anabolic signaling), the combination is more effective than dose-escalation of either single agent. Single-agent dose escalation beyond the linear range of the dose-response relationship carries the risk of disproportionate side effects, whereas the combination achieves supra-additive GH response at modest doses of each component. This is a pharmacologically and ethically more favorable strategy in in-vivo research.

Where to Buy

The Tesamorelin 6mg + Ipamorelin 2mg combination vial reviewed here is available through Apollo Peptide Sciences. For full vendor details, current pricing, lot-specific CoA access, and shipping information, see our dedicated product page, where the affiliate link is managed through our standard disclosure process (see disclosure policy).

Before purchasing any research peptide, researchers should confirm that their institution has appropriate authorization for peptide hormone research, that a suitable biosafety protocol is in place, and that their research design has been reviewed by an ethics or institutional review board where applicable. For guidance on evaluating supplier quality, reading CoA documents, and comparing vendors, see our supplier evaluation guide.

When comparing vendors, the key parameters to assess are: peptide purity (greater than or equal to 98% HPLC), mass spectrometry identity confirmation, endotoxin testing, cold-chain shipping infrastructure, and responsiveness to analytical queries. Apollo Peptide Sciences provides lot-specific CoA documentation and maintains cold-chain shipping protocols, which are consistent with current standards for research-grade peptide supply.

FAQ